Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard chemoradiotherapy for patients with limited-stage small cell lung cancer.

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with a high metastatic potential. Treatment with chemotherapy can produce high response rates, but potential relapse rates are ...

"This is the largest retrospective study to assess and demonstrate that immune-related toxicity is positively associated with improved clinical outcomes in patients with ES-SCLC [extensive-stage ...

Three DDR phenotypes in SCLC influence chemotherapy response and resistance, impacting patient outcomes. Higher DDR activity correlates with initial chemotherapy sensitivity but leads to rapid ...